AlphAIalphai — Financial news for AI agents
SEC EDGARJUL 312 min read$IQV

BOUSBIB ARI sold $26.1M of IQV

BOUSBIB ARI (See Remarks) sold 106,279 shares of IQVIA HOLDINGS INC. (IQV) at an average of $245.51 ($244.78–$247.10, $26.09M total) across 4 trades on 2026-07-29.

Original reporting
SEC EDGAR · BOUSBIB ARI
Published Jul 31, 2026, 9:02 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 31, 2026, 9:06 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$IQV
Neutral
low confidence
Mentioned
$IQV
Relevance
7/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$IQVNeutralLow
01

Why it matters

The newest fact is the disclosed sale size ($26.09M) and the trade price range ($244.78 to $247.10) by an officer/director on 2026-07-29.

02

Market read

Traders may monitor for follow-on insider activity or interpret the sale as mild negative sentiment, but there is no new operating or financial guidance in the filing.

03

What to watch

The text does not state whether the sale was part of a broader program, tax event, or diversification plan, and it provides no context on prior insider activity.

Relevance 7/10Novelty 5/10Timing: filed 2026-07-31 after trades dated 2026-07-29

Background

This is an SEC Form 4 insider transaction disclosure for IQVIA Holdings Inc.

Company-level read

Ticker impact

$IQVNeutralLow confidence
Context

IQVIA Form 4 shows officer/director BOUSBIB ARI sold $26.1M of IQV shares in open-market transactions at $244.78 to $247.10 on 2026-07-29.

Expected impact

Likely limited, short-lived sentiment impact unless follow-on selling or new fundamentals emerge.

Evidence & confidence

The filing is a routine Form 4 insider sale with no 10b5-1 plan stated and no accompanying company-specific operational update in the text.

Market effects

Sector

No sector-wide read-through is provided; this is company-specific insider activity only.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Insider sales can be planned for liquidity or diversification, so the signal may be overstated without evidence of distress or a 10b5-1 plan.

Key entities

  • issuer
    IQVIA HOLDINGS INC.

    Subject of the Form 4 insider sale disclosure.

  • insider
    BOUSBIB ARI

    Officer and director who sold 106,279 shares across four trades.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

IQV insider trading history →

Related articles

AUG 30
$IQVHighAI 9/10

Will IQVIA’s Upgraded 2026 Guidance and Bookings Strength Change IQVIA Holdings' (IQV) Narrative

IQVIA Holdings (IQV) reported Q2 earnings that beat expectations, with adjusted earnings up 12.1% and revenue up 8.7% year over year. The company raised its 2026 guidance for revenue, adjusted EBITDA, and earnings, citing strong bookings and acquisitions. Management attributes the upgrade to broad-based demand and operational efficiency, including AI-driven initiatives like IQVIA.ai. The stock is projected to reach $20.4 billion in revenue and $2.0 billion in earnings by 2029, representing a 5%

simplywall.st2 min
AUG 9
$IQVMed

How IQVIA’s Medera Cardiac Gene Therapy Alliance and Raised 2026 Outlook Will Impact IQV (IQV) Investors

IQVIA Inc. said it raised full-year 2026 revenue guidance to US$17.28–US$17.48 billion, with Q3 outlook of US$4.32–US$4.39 billion, alongside reporting Q2 results and buyback activity. IQVIA also announced a collaboration with Medera Inc. on cardiac gene therapies and human-based drug discovery, linking IQVIA trial and platform capabilities to Medera programs.

simplywall.st6 min
AUG 4
$IQVMed

5 Insightful Analyst Questions From IQVIA’s Q2 Earnings Call

IQVIA reported Q2 CY2026 results with revenue of $4.37B versus $4.30B estimates and adjusted EPS of $3.15 versus $3.03, with adjusted EBITDA of $994M. Management cited 6% organic growth and strong net new bookings. Full-year revenue guidance was lifted to $17.38B and adjusted EPS to $12.90. Analysts discussed bookings, outsourcing, AI, M&A, and margins.

financialcontent.com6 min
AUG 2
Med

An IQVIA CEO Sold $26.1 Million as Bookings Hit a Record $3.15 Billion

IQVIA Holdings CEO sold about $26.1 million of stock appreciation rights with a Feb 2027 expiration, while retaining a large share position, according to the filing and article. The company reported Q2 revenue up 8.7% to $4.37B, adjusted EPS up 12.1% to $3.15, and record clinical bookings of $3.15B, raising full-year guidance to $17.475B.

yahoo.com5 min